Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Türkiye

Coordination and Support Action · Running

OmegaTree OmegaTree: MAS-10® Enabled Metabolomics and AI-Driven Precision Nutrition and Health Analytics Platform

Coordinator
Hematainer Biyoteknoloji ve Saglik Urunleri Anonim Sirketi, Türkiye
Runs
1 August 2026 to 31 July 2028
Status
Running
EU funding
€500k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310496

What the project is doing

In the project's own words, from its summary on CORDIS.

OmegaTree is developing MAS-10®, a patented volumetric microsampling system enabling accurate, hematocrit-independent blood collection from a simple finger-prick, stable at room temperature and validated in licensed laboratories. Unlike dried blood spot or VAMS devices, MAS-10® is compatible with advanced metabolomics (LC-MS/MS, GC-MS, ICP-MS) and is being expanded to measure amino acids, fatty acids, SCFAs, organic acids, trace elements, and oxidative stress markers (8-OHdG).

An AI-driven reporting platform integrates these biomarkers with nutrition data to deliver personalized dietary and health insights. Early pilots confirm compatibility with next-generation sequencing, opening the path toward multi-omics precision health. The project addresses the urgent global need for scalable solutions against obesity, diabetes, and other non-communicable diseases, directly aligned with UN SDG 3 and the EU Precision Nutrition Pathfinder Challenge.

Target users include individuals, clinics, dietitians, functional medicine experts, wellness units in hospitals, supplement companies, and corporate health programs. With CE-IVD self-declared kits, UTS registration, national funding, and ethics-approved clinical trials, MAS-10® is ready for TRL 6 validation. The core team combines expertise in biostatistics, medical biochemistry, engineering, nutrition & dietetics, analytical chemistry, and molecular biology.

It is supported by Erciyes Technopark and Technology Transfer Office for IP management, business development, and commercialization, alongside external regulatory consultants. Over the next 12–24 months, we will optimize the device, expand biomarker panels, conduct a randomized controlled trial in obese individuals, enhance AI reporting, and refine business/regulatory pathways. This Pre-Accelerator project will deliver a clinically validated, market-ready precision nutrition platform at TRL 6, while laying the foundation for TRL 7–9 scale-up and an EIC Accelerator application.

Topics

Who is involved

OrganisationCityCountryRole
Hematainer Biyoteknoloji ve Saglik Urunleri Anonim SirketiMelikgazi/KayseriTürkiyeCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI